Read the following passage about GLP-1 Therapies: A Global Health Initiative and mark the letter A, B, C or D on your answer sheet to indica...

Read the following passage about GLP-1 Therapies: A Global Health Initiative and mark the letter A, B, C or D on your answer sheet to indicate the option that best fits each of the numbered blanks from 18 to 22.

The World Health Organization has recently recommended GLP-1 therapies for obesity treatment in many countries around the world. These medicines, which include semaglutide and tirzepatide, (18)_________. If governments had taken decisive action earlier on obesity prevention programs, the expected cost of three trillion dollars per year by 2030 would have been avoided completely. Obesity is now recognized as a chronic disease requiring professional medical supervision, not just a lifestyle problem or personal choice.

(19)_________. The fact that fewer than ten percent of people who need these medicines will have them by 2030 shows serious and ongoing problems throughout the healthcare system. (20)_________. Most developing countries and poor communities cannot afford these expensive treatments for their citizens at all.

The WHO warns about serious manufacturing challenges and bottlenecks; furthermore, health systems in poor countries face many severe difficulties and resource shortages. These systemic factors prevent more people from receiving GLP-1 therapies effectively. Some GLP-1 drugs have been successfully added to the essential medicines list for diabetes treatment, (21)_________. The organization plans to work cooperatively with governments and international partners from 2026 onwards to improve access and lower prices significantly.

If countries invest in better production facilities and comprehensive support programs, more people could benefit from these important treatments. (22)_________, private businesses, and health organizations worldwide. Without immediate action and commitment, obesity will continue to cost the world billions of dollars annually and cause serious health problems for millions of vulnerable people everywhere.

https://www.reuters.com/tc

Question 18:

A. have been used to manage chronic diseases in people with obesity-related issues

B. serve for extended treatment among obese adults having significant metabolic conditions

C. are used for long-term care in adults with obesity and related health conditions

D. are provided during long-term management of patients with obesity complications

Question 19:

A. Still, procurement for particular medicines becomes substantially constrained but difficult everywhere

B. Nevertheless, availability of treatment options proves severely restricted yet problematic worldwide

C. However, access to these drugs remains very limited and challenging globally

D. Yet, obtaining pharmaceutical therapy stays quite restricted or problematic internationally

Question 20:

A. High costs and limited production capacity are the main barriers preventing wider distribution

B. Limited funding and weak capacity is the primary obstacle preventing much wider market accessibility

C. Production issues but financial constraints remain the main challenge limiting broader market distribution

D. Expensive output yet insufficient capacity are the key barrier preventing broader distribution

Question 21:

A. which is a positive and encouraging step forward for patients globally

B. where exists a favorable and uplifting initiative ahead for recipients globally

C. were beneficial and inspiring moves ahead to individuals worldwide

D. have been a favorable and uplifting development onward toward recipients around the world

Question 22:

A. What the solution requires is close cooperation between governments

B. How the plan demands is thorough collaboration among agencies

C. Whether the strategy needs is unified partnership among institutions

D. Where the initiative involves is broad coordination between organizations